Analysis of the risk factors and their combinations in acute gastroduodenal ulcer bleeding: A case-control study

Scandinavian Journal of Gastroenterology

Volumn 42, Issue 12, 2007, Pages 1395-1403

  Udd, Marianne ^a,c   Miettinen, Pekka ^b   Palmu, Antero ^a   Heikkinen, Markku ^b   Janatuinen, Esko ^b   Pasanen, Pentti ^b   Tarvainen, Riitta ^b   Mustonen, Harri ^c   Julkunen, Risto ^b  

^a Central Finland Central Hospital   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

ASA; CagA; Dose dependence; Duodenal ulcer; Gastric ulcer H. pylori infection; NSAID; Peptic ulcer bleeding; Risk factor; Smoking

Indexed keywords

ACETYLSALICYLIC ACID; CAGA PROTEIN; DICLOFENAC; IBUPROFEN; IMMUNOGLOBULIN G; INDOMETACIN; KETOPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; UREASE;

ADULT; ANALYTIC METHOD; ARTICLE; BACTERIAL INFECTION; CASE CONTROL STUDY; CIGARETTE SMOKING; COMPARATIVE STUDY; CONTROLLED STUDY; ENDOSCOPY; FEMALE; GASTRODUODENAL ULCER; HELICOBACTER PYLORI; HISTOLOGY; HUMAN; IMMUNOBLOTTING; MAJOR CLINICAL STUDY; MALE; PAIN; PRIORITY JOURNAL; QUESTIONNAIRE; RISK; RISK FACTOR; SMOKING; THROMBOSIS;

ACUTE DISEASE; ADULT; ALCOHOL DRINKING; ANALGESICS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICOAGULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LOGISTIC MODELS; MALE; PEPTIC ULCER HEMORRHAGE; QUESTIONNAIRES; RISK FACTORS; SMOKING; STATISTICS, NONPARAMETRIC;

EID: 36249023170     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365520701478758     Document Type: Article

References (50)

1. Rockall TA, Logan RF, Devlin HB, Northfield TC. Incidence of and mortality from acute upper gastrointestinal haemorrhage in the United Kingdom. Steering Committee and members of the National Audit of Acute Upper Gastrointestinal Haemorrhage. Br Med J 1995;311:222-6.
2. Arlt GD, Leyh M. Incidence and pathophysiology of peptic ulcer bleeding. Langenbecks Arch Surg 2001;386:75-81.
3. Higham J, Kang JY, Majeed A. Recent trends in admissions and mortality due to peptic ulcer in England: increasing frequency of haemorrhage among older subjects. Gut 2002; 50:460-4.
4. Rockall TA, Logan RF, Devlin HB, Northfield TC. Variation in outcome after acute upper gastrointestinal haemorrhage. The National Audit of Acute Upper Gastrointestinal Haemorrhage. Lancet 1995;346:346-50.
5. Vreeburg EM, Snel P, de Bruijne JW, Bartelsman JF, Rauws EA, Tytgat GN. Acute upper gastrointestinal bleeding in the Amsterdam area: incidence, diagnosis, and clinical outcome. Am J Gastroenterol 1997;92:236-43.
6. Lanas A, Garcia-Rodriguez LA, Arroyo MT, Gomollon F, Feu F, Gonzalez Perez A, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective COX-2 inhibitors, traditional non-aspirin NSAIDs, aspirin, and combinations. Gut 2006;55:1731-8.
7. Lanza FL. Gastrointestinal toxicity of newer NSAIDs. Am J Gastroenterol 1993;88:1318-23.
8. Leivonen M, Kivilaakso E. Peptic ulcer bleeding today: risk factors and characteristics of the disease. Scand J Gastroenterol 1991;26:1013-9.
9. Savage RL, Moller PW, Ballantyne CL, Wells JE. Variation in the risk of peptic ulcer complications with nonsteroidal antiinflammatory drug therapy. Arthritis Rheum 1993;36: 84-90.
10. Weil J, Colin-Jones D, Langman M, Lawson D, Logan R, Murphy M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. Br Med J 1995;310:827-30.
11. Covacci A, Censini S, Bugnoli M, Petracca R, Burroni D, Macchia G, et al. Molecular characterization of the 128-kDa immunodominant antigen of Helicobacter pylori associated with cytotoxicity and duodenal ulcer. Proc Natl Acad Sci USA 1993;90:5791-5.
12. Stack WA, Atherton JC, Hawkey GM, Logan RF, Hawkey CJ. Interactions between Helicobacter pylori and other risk factors for peptic ulcer bleeding. Aliment Pharmacol Ther 2002;16:497-506.
13. Schubert TT, Bologna SD, Nensey Y, Schubert AB, Mascha EJ, Ma CK. Ulcer risk factors: interactions between Helicobacter pylori infection, nonsteroidal use, and age. Am J Med 1993;94:413-8.
14. Hernandez-Diaz S, Varas-Lorenzo C, Garcia Rodriguez LA. Non-steroidal anti-inflammatory drugs and the risk of acute myocardial infarction. Basic Clin Pharmacol Toxicol 2006; 98:266-74.
15. Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 2006;116: 4-15.
16. Forrest JA, Finlayson ND, Shearman DJ. Endoscopy in gastrointestinal bleeding. Lancet 1974;2:394-7.
17. Finnish statistics of medicines 1996. Helsinki: National agency for Medicines and Social Insurance Institution, Helsinki; 1997.
18. Hsu PI, Lai KH, Tseng HH, Lin CK, Lo GH, Cheng JS, et al. Risk factors for presentation with bleeding in patients with Helicobacter pylori-related peptic ulcer diseases. J Clin Gastroenterol 2000;30:386-91.
19. Wu CY, Poon SK, Chen GH, Chang CS, Yeh HZ. Interaction between Helicobacter pylori and non-steroidal anti-inflammatory drugs in peptic ulcer bleeding. Scand J Gastroenterol 1999;34:234-7.
20. Labenz J, Peitz U, Kohl H, Kaiser J, Malfertheiner P, Hackelsberger A, et al. Helicobacter pylori increases the risk of peptic ulcer bleeding: a case-control study. Ital J Gastroenterol 1999;31:110-5.
21. Cullen DJ, Hawkey GM, Greenwood DC, Humphreys H, Shepherd V, Logan RF, et al. Peptic ulcer bleeding in the elderly: relative roles of Helicobacter pylori and non-steroidal anti-inflammatory drugs. Gut 1997;41:459-62.
22. Santolaria S, Lanas A, Benito R, Perez-Aisa M, Montoro M, Sainz R. Helicobacter pylori infection is a protective factor for bleeding gastric ulcers but not for bleeding duodenal ulcers in NSAID users. Aliment Pharmacol Ther 1999;13: 1511-8.
23. Aalykke C, Lauritsen JM, Hallas J, Reinholdt S, Krogfelt K, Lauritsen K. Helicobacter pylori and risk of ulcer bleeding among users of nonsteroidal anti-inflammatory drugs: a case-control study. Gastroenterology 1999;116:1305-9.
24. Henriksson AE, Edman AC, Nilsson I, Bergqvist D, Wadstrom T. Helicobacter pylori and the relation to other risk factors in patients with acute bleeding peptic ulcer. Scand J Gastroenterol 1998;33:1030-3.
25. Gisbert JP, Gonzalez L, de Pedro A, Valbuena M, Prieto B, Llorca I, et al. Helicobacter pylori and bleeding duodenal ulcer: prevalence of the infection and role of non-steroidal anti-inflammatory drugs. Scand J Gastroenterol 2001;36: 717-24.
26. Pilotto A, Leandro G, Di Mario F, Franceschi M, Bozzola L, Valerio G. Role of Helicobacter pylori infection on upper gastrointestinal bleeding in the elderly: a case-control study. Dig Dis Sci 1997;42:586-91.
27. Imhof M, Ohmann C, Hartwig A, Thon KP, Hengels KJ, Roher HD. Which peptic ulcers bleed? Results of a case-control study. DUSUK Study Group. Scand J Gastroenterol 1997;32:131-8.
28. Ng TM, Fock KM, Khor JL, Teo EK, Sim CS, Tan AL, et al. Non-steroidal anti-inflammatory drugs, Helicobacter pylori and bleeding gastric ulcer. Aliment Pharmacol Ther 2000;14:203-9.
29. Tzourmakliotis D, Economou M, Manolakopoulos S, Bethanis S, Bergele C, Lakoumentas J, et al. Clinical significance of cytotoxin-associated gene A status of Helicobacter pylori among non-steroidal anti-inflammatory drug users with peptic ulcer bleeding: a multicenter case-control study. Scand J Gastroenterol 2004;39:1180-5.
30. Hallas J, Dall M, Andries A, Andersen BS, Aalykke C, Hansen JM, et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population-based case-control study. Br Med J 2006; 333:726-30.
31. Garcia Rodriguez LA, Barreales Tolosa L. Risk of upper gastrointestinal complications among users of traditional NSAIDs and COXIBs in the general population. Gastroenterology 2007;132:498-506.
32. Weil J, Langman MJ, Wainwright P, Lawson DH, Rawlins M, Logan RF, et al. Peptic ulcer bleeding: accessory risk factors and interactions with non-steroidal anti-inflammatory drugs. Gut 2000;46:27-31.
33. Udd M, Miettinen P, Palmu A, Julkunen R. Effect of short-term treatment with regular or high doses of omeprazole on the detection of Helicobacter pylori in bleeding peptic ulcer patients. Scand J Gastroenterol 2003;38:588-93.
34. Go MF, Graham DY. Presence of the cagA gene in the majority of Helicobacter pylori strains is independent of whether the individual has duodenal ulcer or asymptomatic gastritis. Helicobacter 1996;1:107-11.
35. Evans DG, Queiroz DM, Mendes EN, Evans DJJR. Helicobacter pylori cagA status and s and m alleles of vacA in isolates from individuals with a variety of H. pylori-associated gastric diseases. J Clin Microbiol 1998;36:3435-7.
36. Hamlet A, Thoreson AC, Nilsson O, Svennerholm AM, Olbe L. Duodenal Helicobacter pylori infection differs in cagA genotype between asymptomatic subjects and patients with duodenal ulcers. Gastroenterology 1999;116:259-68.
37. Park SM, Park J, Kim JG, Cho HD, Cho JH, Lee DH, et al. Infection with Helicobacter pylori expressing the cagA gene is not associated with an increased risk of developing peptic ulcer diseases in Korean patients. Scand J Gastroenterol 1998;33:923-7.
38. Lewis SC, Langman MJ, Laporte JR, Matthews JN, Rawlins MD, Wiholm BE. Dose-response relationships between individual nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: a meta-analysis based on individual patient data. Br J Clin Pharmacol 2002;54:320-6.
39. Vreeburg EM, de Bruijne HW, Snel P, Bartelsman JW, Rauws EA, Tytgat GN. Previous use of non-steroidal antiinflammatory drugs and anticoagulants: the influence on clinical outcome of bleeding gastroduodenal ulcers. Eur J Gastroenterol Hepatol 1997;9:41-4.
40. Andersen IB, Jorgensen T, Bonnevie O, Gronbaek M, Sorensen TI. Smoking and alcohol intake as risk factors for bleeding and perforated peptic ulcers: a population-based cohort study. Epidemiology 2000;11:434-9.
41. Brzozowski T, Konturek PC, Moran AP, Kwiecien S, Pajdo R, Konturek SJ, et al. Enhanced resistance of gastric mucosa to damaging agents in the rat stomach adapted to Helicobacter pylori lipopolysaccharide. Digestion 2003;67: 195-208.
42. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002;359: 14-22.
43. Younossi ZM, Strum WB, Schatz RA, Teirstein PS, Cloutier DA, Spinks TJ. Effect of combined anticoagulation and low-dose aspirin treatment on upper gastrointestinal bleeding. Dig Dis Sci 1997;42:79-82.
44. Kane S, Borisov NN, Brixner D. Pharmacoeconomic evaluation of gastrointestinal tract events during treatment with risedronate or alendronate: a retrospective cohort study. Am J Managed Care 2004;10:S216-26.
45. Kaplan RC, Heckbert SR, Koepsell TD, Rosendaal FR, Psaty BM. Use of calcium channel blockers and risk of hospitalized gastrointestinal tract bleeding. Arch Intern Med 2000;160:1849-55.
46. de Abajo FJ, Montero D, Rodriguez LA, Madurga M. Antidepressants and risk of upper gastrointestinal bleeding. Basic Clin Pharmacol Toxicol 2006;98:304-10.
47. Yuan Y, Tsoi K, Hunt RH. Selective serotonin reuptake inhibitors and risk of upper GI bleeding: confusion or confounding? Am J Med 2006;119:719-27.
48. Smalley WE, Ray WA, Daugherty JR, Griffin MR. No association between calcium channel blocker use and confirmed bleeding peptic ulcer disease. Am J Epidemiol 1998;148:350-4.
49. Graham DY, Malaty HM. Alendronate gastric ulcers. Aliment Pharmacol Ther 1999;13:515-9.
50. Wessinger S, Kaplan M, Choi L, Williams M, Lau C, Sharp L, et al. Increased use of selective serotonin reuptake inhibitors in patients admitted with gastrointestinal haemorrhage: a multicentre retrospective analysis. Aliment Pharmacol Ther 2006;23:937-44.